Vemurafenib Mechanism of Action: Targeting BRAF V600E in Cancer Therapy #204363 (License: Personal Use)

This scientific illustration depicts the molecular mechanism of vemurafenib (PLX4032), a selective BRAF V600E inhibitor used in targeted cancer therapy. By binding to the mutated BRAF protein, vemurafenib prevents ATP-dependent phosphorylation of MEK, thereby interrupting the MAPK signaling cascade that drives uncontrolled cell division. The diagram highlights RTK activation upstream and the resulting suppression of ERK-mediated cellular proliferation.

Used in oncology educational materials, clinical guidelines, or pharmaceutical webpages explaining targeted therapy for BRAF-mutant melanoma; matches user intent seeking mechanistic understanding of vemurafenib’s action.